Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing novel antiviral therapeutics to address the global need for effective and safe treatments for serious and chronic viral diseases. The company leverages unique structure-based technologies and Nobel Prize-winning expertise to create viable antiviral drugs. Headquartered in Bothell, Washington, Cocrystal Pharma aims to develop broad-spectrum antiviral solutions.

The company's pipeline focuses on antiviral therapeutics that target the replication process of various viruses, including norovirus, influenza viruses, coronaviruses (such as SARS-CoV-2 and MERS-CoV), and hepatitis C virus (HCV). Key product candidates include CDI-988, an oral pan-viral protease inhibitor currently in a Phase 1b clinical trial for norovirus prevention and treatment, which has received FDA Fast Track designation. Another candidate, CC-42344, is a novel PB2 inhibitor in Phase 2a clinical trials for influenza A. Cocrystal Pharma also has collaboration agreements with Merck Sharp & Dohme Corp. for influenza A/B antiviral agents and with Kansas State University Research Foundation for norovirus and coronavirus infections.

In recent news, James Sapirstein was appointed as Chief Executive Officer in June 2026. The company also announced the discovery of pan-viral inhibitors targeting hantavirus, bunyavirus, and influenza in May 2026. Cocrystal Pharma continues to advance its antiviral product pipeline, with CDI-988 progressing through clinical studies and the company reporting its Q1 2026 financial results, which included an initial payment from an NIH SBIR grant for its influenza A/B inhibitor program.